Products sold in the past by Zynex for pain management have failed to penetrate the market. Zynex's new products are radically different from their predecessors: more specific and innovative. The new ...
Demand for pain management devices is climbing worldwide, fueled by several major trends. As chronic disease rates soar, the need for effective, drug-free pain solutions has grown more pressing. At ...
Throughout the last three months, 4 analysts have evaluated Zynex (NASDAQ:ZYXI), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ...
In the second quarter, Zynex grew revenue by 11% to $49.9 million with earnings per share (EPS) of $0.04, which was actually down 55% from the $0.09 print in the year-ago quarter. Both figures missed ...
Today, we put pain management therapy concern Zynex, Inc. in the spotlight for the first time. Revenues are growing at a healthy clip and the company is nicely profitable. However, Zynex, Inc. stock ...
Zynex has been granted FDA clearance for its NexWave electrotherapy device, according to a Zynex news release. NexWave delivers three modalities of stimulation: interferential, neuromuscular ...
Shares of pain-management equipment specialist Zynex (NASDAQ: ZYXI) were falling in Friday trading, down as much as 23.4%, before recovering to a 13.4% decline as of 3:25 p.m. EDT. The medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback